December 1 - 3, 2008
International Centre for Genetic Engineering & Biotechnology
ICGEB Campus, New Delhi,
One third of the global population is believed to be infected with Mycobacterium tuberculosis (MTB), accounting for nearly eight million cases of active tuberculosis (TB) annually with an estimated death toll of more than 2 million per year. Incidence has been accelerated by the HIV epidemic and the appearance of new genotypes and multi-drug resistant (MDR) and extensively drug resistant (XDR) strains of MTB. The conventional control measures have had little impact on the relentless march of the TB epidemic. Despite extensive work on unravelling the intricate molecular interactions between MTB and the human host, the ground reality of TB epidemic remains as grim as ever, with the diagnosis, treatment and vaccine
The Symposium will provide an opportunity to take stock of deliverables in the areas of diagnostics, drugs and vaccines for tuberculosis in the light of advances made in the basic biology of the host-pathogen interaction. More importantly, the Symposium will look for future directions to emerge in these areas so as to provide succor to patients at the point-of-care facilities.
The Poster Session will provide additional opportunity for extended interactions leading to potential North-South, and South-South collaborations in our collective effort to tame the world’s most successful pathogen, MTB. Some outstanding Abstracts submitted for Poster Session will be selected for short oral presentations at the Plenary Sessions.
Scientific Sessions:
1. Metabolomics of Mycobacteria: Developing new TB drugs
2. The Host and The Pathogen: Genomic and Cell Biology of the interaction
3. TB vaccine(s): Emerging Strategies
4. Biomarkers: Trailing the bug
5. Poster Session on all of above themes to be contributed by participating
delegates
Deadline for submitting Abstract: 15th September 2008
Deadline for Registration: 15th October 2008
0 Comments